


SUPPLEMENTARY FIGURE



Supplementary Figure 1. Incidence of primary and secondary outcomes: Xa-I vs. dabigatran (total original cohort). The incidence of cardiovascular events and arteriosclerotic disease was significantly lower in the Xa-I group than in the dabigatran group. The incidence of congestive heart failure and cardiovascular death did not differ between the groups. Abbreviations: CI, confidence interval; HR, hazard ratio; Xa-I, Factor Xa inhibitor.